Ratio Therapeutics secured a $70 million Series C to support radiopharmaceutical trial activity, according to the company’s funding announcement. The round includes participation from existing investors such as Duquesne Family Office and Bristol Myers Squibb, alongside new backers. The financing is framed as runway for advancing radiopharma candidates through clinical development, with the company positioning its program toward additional clinical readouts and operational buildout. The deal reinforces investor appetite for radiopharmaceuticals, where capital needs are often driven by manufacturing readiness, trial execution, and imaging/biomarker strategy tied to early efficacy signals.